Cancer Family
Leukemia
CI-CAN-00000215Explore in graph →
HematologicTop-level1,769 active trials42 approved drugs708 evidence items
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000215Explore in graph →
Clinical trials
8,437 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (1,348)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT02458014 | Blinatumomab in Treating Patients With B-cell Acute Lymphoblastic Leukemia With Minimal Residual Disease | completed | Phase 2 | 37 | M.D. Anderson Cancer CenterOTHER | 1 | Sep 25, 2026 | clinicaltrials |
| NCT02649387 | Ibrutinib in Treating Minimal Residual Disease in Patients With Chronic Lymphocytic Leukemia After Front-Line Therapy(MERIT) | completed | Phase 2 | 35 | Mayo ClinicOTHER | 1 | Sep 25, 2026 | clinicaltrials |
| NCT03342144 | Study of the Use of Venetoclax in Participants With Chronic Lymphocytic Leukemia (CLL) Under Real-Life Setting(VeRVe) | recruiting | — | 500 | AbbVieINDUSTRY | 3 | Sep 25, 2026 | clinicaltrials |
| NCT03629171 | Liposome-encapsulated Daunorubicin-Cytarabine and Venetoclax in Treating Participants With Relapsed, Refractory or Untreated Acute Myeloid Leukemia | recruiting | Phase 2 | 72 | M.D. Anderson Cancer CenterOTHER | 1 | Sep 25, 2026 | clinicaltrials |
| NCT03702309 | Liquid Biopsy Evaluation and Repository Development at Princess Margaret(LIBERATE) | recruiting | — | 2,500 | University Health Network, TorontoOTHER | 1 | Sep 25, 2026 | clinicaltrials |
| NCT03779854 | Naive T Cell Depletion for Preventing Chronic Graft-versus-Host Disease in Children and Young Adults With Blood Cancers Undergoing Donor Stem Cell Transplant | active not recruiting | Phase 2 | 45 | Fred Hutchinson Cancer CenterOTHER | 1 | Sep 25, 2026 | clinicaltrials |
| NCT04679012 | Polatuzumab Vedotin in Combination With Chemotherapy in Subjects With Richter's Transformation | active not recruiting | Phase 2 | 20 | Weill Medical College of Cornell UniversityOTHER | 1 | Sep 25, 2026 | clinicaltrials |
| NCT04811560 | A Phase 1/2 Study of Bleximenib in Participants With Acute Leukemia (cAMeLot-1)(cAMeLot-1) | recruiting | Phase 1 / Phase 2 | 420 | Janssen Research & Development, LLCINDUSTRY | 13 | Sep 25, 2026 | clinicaltrials |
| NCT04925479 | Study to Determine the Dose and Safety of Asciminib in Pediatric Patients With Chronic Myeloid Leukemia | recruiting | Phase 1 / Phase 2 | 34 | Novartis PharmaceuticalsINDUSTRY | 14 | Sep 25, 2026 | clinicaltrials |
| NCT05023980 | A Study of Pirtobrutinib (LOXO-305) Versus Bendamustine Plus Rituximab (BR) in Untreated Patients With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)(BRUIN-CLL-313) | active not recruiting | Phase 3 | 282 | Loxo Oncology, Inc.INDUSTRY | 20 | Sep 25, 2026 | clinicaltrials |
| NCT05453903 | A Study of Bleximenib in Combination With Acute Myeloid Leukemia (AML) Directed Therapies | active not recruiting | Phase 1 | 196 | Janssen Research & Development, LLCINDUSTRY | 8 | Sep 25, 2026 | clinicaltrials |
| NCT05564390 | MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial) | recruiting | Phase 2 | 2,000 | National Cancer Institute (NCI)NIH | 3 | Sep 25, 2026 | clinicaltrials |
| NCT05673057 | Study of MP0533 in Patients Acute Myeloid Leukemia or Myelodysplastic Syndrome | completed | Phase 1 | 80 | Molecular Partners AGINDUSTRY | 4 | Sep 25, 2026 | clinicaltrials |
| NCT05886491 | A Study of GDX012 in Adults With Relapsed or Refractory Acute Myeloid Leukemia | terminated | Phase 1 / Phase 2 | 16 | TakedaINDUSTRY | 2 | Sep 25, 2026 | clinicaltrials |
| NCT05963074 | A Study to Customize Ibrutinib Treatment Regimens for Participants With Previously Untreated Chronic Lymphocytic Leukemia(TAILOR) | active not recruiting | Phase 2 | 333 | Janssen Research & Development, LLCINDUSTRY | 8 | Sep 25, 2026 | clinicaltrials |
| NCT06144606 | Study of KTE-X19 in Minimal Residual Disease (MRD) Positive B-Cell Acute Lymphoblastic Leukemia (B-ALL) | recruiting | Phase 2 | 60 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 1 | Sep 25, 2026 | clinicaltrials |
| NCT06236724 | Phase II Study Assessing Efficacy and Safety of Asciminib in Patients With Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase. | recruiting | Phase 2 | 150 | M.D. Anderson Cancer CenterOTHER | 1 | Sep 25, 2026 | clinicaltrials |
| NCT06299540 | Benefits of Individual Physical Activity Intervention on Health-related Quality of Life in Participants With Chronic Lymphocytic Leukemia(QOLIBRI) | recruiting | — | 180 | Janssen Cilag S.A.S.INDUSTRY | 1 | Sep 25, 2026 | clinicaltrials |
| NCT06317662 | Testing the Addition of the Anti-cancer Drug Venetoclax and/or the Anti-cancer Immunotherapy Blinatumomab to the Usual Chemotherapy Treatment for Infants With Newly Diagnosed KMT2A-rearranged or KMT2A-non-rearranged Leukemia | recruiting | Phase 2 | 153 | National Cancer Institute (NCI)NIH | 2 | Sep 25, 2026 | clinicaltrials |
| NCT06401603 | A Phase I Study of Decitabine, Lisaftoclax, and Olverembatinib in Patients With Advanced Chronic Myeloid Leukemia and Philadelphia Chromosome-Positive Acute Myeloid Leukemia | recruiting | Phase 1 | 30 | M.D. Anderson Cancer CenterOTHER | 1 | Sep 25, 2026 | clinicaltrials |
| NCT06476665 | A Study to Learn About the Safety of BESPONSA Injection in Pediatric Patients With Acute Lymphocytic Leukemia. | active not recruiting | — | 12 | PfizerINDUSTRY | 1 | Sep 25, 2026 | clinicaltrials |
| NCT06548152 | AQUALIS:QoL of CLL Patients Treated With Acalabrutinib in France, Retrospective Study Based on Data From PLATON Database(AQUALIS) | recruiting | — | 120 | AstraZenecaINDUSTRY | 1 | Sep 25, 2026 | clinicaltrials |
| NCT06548230 | A Phase 1B/2A Trial of NADUNOLIMAB in Combination With Azacitidine (With/Without Venetoclax) in Patients With Myelodysplastic Syndrome (MDS) and Acute Myelogenous Leukemia (AML) | recruiting | Phase 1 / Phase 2 | 40 | M.D. Anderson Cancer CenterOTHER | 1 | Sep 25, 2026 | clinicaltrials |
| NCT06618001 | A Study of JNJ-89853413 for Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Neoplasms | active not recruiting | Phase 1 | 64 | Janssen Research & Development, LLCINDUSTRY | 3 | Sep 25, 2026 | clinicaltrials |
| NCT06788509 | A Rollover Study for Continued Study Treatment and Ongoing Safety Monitoring | enrolling by invitation | Phase 1 | 120 | Janssen Research & Development, LLCINDUSTRY | 15 | Sep 25, 2026 | clinicaltrials |
| NCT06820268 | A Study of XS-04 in Patients With Relapsed or Refractory Hematologic Malignancies | recruiting | Phase 1 | 168 | Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd.INDUSTRY | 1 | Sep 25, 2026 | clinicaltrials |
| NCT06852222 | A Study of Bleximenib, Venetoclax and Azacitidine For Treatment of Participants With Newly Diagnosed Acute Myeloid Leukemia (AML)(cAMeLot-2) | recruiting | Phase 3 | 600 | Janssen Research & Development, LLCINDUSTRY | 25 | Sep 25, 2026 | clinicaltrials |
| NCT07211958 | Study of Revumenib in Combination With Intensive Chemotherapy in Newly Diagnosed Acute Myeloid Leukemia (AML) With a NPM1 Mutation(REVEAL-ND NPM1) | recruiting | Phase 3 | 468 | Syndax PharmaceuticalsINDUSTRY | 23 | Sep 25, 2026 | clinicaltrials |
| NCT07269470 | Phase II Study Assessing the Safety and Efficacy of Dasatinib in Combination With Ropeginterferon in Patients With Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase | recruiting | Phase 2 | 40 | M.D. Anderson Cancer CenterOTHER | 1 | Sep 25, 2026 | clinicaltrials |
| NCT07295951 | A Study of 14C-Bleximenib (Radiolabeled) in Participants With Acute Leukemia | completed | Phase 1 | 6 | Janssen Research & Development, LLCINDUSTRY | 1 | Sep 25, 2026 | clinicaltrials |
| NCT07570173 | A Clinical Trial of MK-1045 in People With B-cell Acute Lymphoblastic Leukemia (MK-1045-005) | recruiting | Phase 2 / Phase 3 | 340 | Merck Sharp & Dohme LLCINDUSTRY | 8 | Sep 25, 2026 | clinicaltrials |
| NCT07602088 | A Real-world Study of Ibrutinib and Venetoclax (I+V) First-Line Treatment Given for Fixed-duration of Time in Participants With Chronic Lymphocytic Leukemia(REALITY-RO) | recruiting | — | 60 | Janssen Research & Development, LLCINDUSTRY | 1 | Sep 25, 2026 | clinicaltrials |
| NCT07709000 | A Clinical Trial of MK-1045 in People With B-cell Cancer (MK-1045-006) | not yet recruiting | Phase 2 | 60 | Merck Sharp & Dohme LLCINDUSTRY | 1 | Sep 25, 2026 | clinicaltrials |
| NCT07714044 | Rutgers University Study of the Genetics of Blood Cancers | recruiting | — | 10,000 | Rutgers, The State University of New JerseyOTHER | 1 | Sep 25, 2026 | clinicaltrials |
| NCT07838714 | Dual-Targeted Umbilical Cord Blood CAR-T Cells Against CD19 and CD22 for the Treatment of Relapsed or Refractory Acute B-Cell Lymphoblastic Leukemia | recruiting | Phase 1 | 18 | Ruijin HospitalOTHER | 1 | Sep 25, 2026 | clinicaltrials |
| NCT07841002 | CLL-1-Targeted In Vivo CAR-T Cell Immunotherapy for Relapsed/Refractory Acute Myeloid Leukemia | not yet recruiting | Phase 1 | 12 | Liping DouOTHER | 1 | Sep 25, 2026 | clinicaltrials |
| NCT03661307 | Quizartinib, Decitabine, and Venetoclax in Treating Participants With Untreated or Relapsed Acute Myeloid Leukemia or High Risk Myelodysplastic Syndrome | recruiting | Phase 1 / Phase 2 | 73 | M.D. Anderson Cancer CenterOTHER | 1 | Sep 24, 2026 | clinicaltrials |
| NCT03874052 | Ruxolitinib in Combination With Venetoclax With and Without Azacitidine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia | recruiting | Phase 1 | 51 | Jennifer SaultzOTHER | 1 | Sep 24, 2026 | clinicaltrials |
| NCT03986034 | Early Clonal Dynamics During Venetoclax Treatment for Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL) | recruiting | Phase 2 | 75 | National Heart, Lung, and Blood Institute (NHLBI)NIH | 1 | Sep 24, 2026 | clinicaltrials |
| NCT04219163 | Chimeric Antigen Receptor T-cells for The Treatment of AML Expressing CLL-1 Antigen | active not recruiting | Phase 1 | 18 | Baylor College of MedicineOTHER | 1 | Sep 24, 2026 | clinicaltrials |
| NCT04728893 | Efficacy and Safety of Nemtabrutinib (MK-1026) in Participants With Hematologic Malignancies (MK-1026-003) | recruiting | Phase 2 | 490 | Merck Sharp & Dohme LLCINDUSTRY | 22 | Sep 24, 2026 | clinicaltrials |
| NCT05044039 | Duvelisib Following Chimeric Antigen Receptor T-Cell Therapy | active not recruiting | Phase 1 | 42 | Washington University School of MedicineOTHER | 1 | Sep 24, 2026 | clinicaltrials |
| NCT05748171 | A Study to Learn More About the Study Medicine Called Inotuzumab Ozogamicin (InO) in Children (1 to <18 Years) With First Relapse ALL | recruiting | Phase 2 | 100 | PfizerINDUSTRY | 15 | Sep 24, 2026 | clinicaltrials |
| NCT05947851 | A Study of Nemtabrutinib Plus Venetoclax vs Venetoclax + Rituximab (VR) in Second-line (2L) + Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) (MK-1026-010/BELLWAVE-010). | recruiting | Phase 3 | 735 | Merck Sharp & Dohme LLCINDUSTRY | 22 | Sep 24, 2026 | clinicaltrials |
| NCT05949125 | Phase 1 Study of Allo-RevCAR01-T-CD123 in Patients With Selected CD123 Positive Hematologic Malignancies (1b Dose Expansion)(RevSTAR-123) | recruiting | Phase 1 | 37 | AvenCell Europe GmbHINDUSTRY | 2 | Sep 24, 2026 | clinicaltrials |
| NCT06071624 | Chimeric Antigen Receptor T Cell Therapy Redirected to CD4 (CD4CAR)as a Second Line Treatment for Chronic Myelomonocytic Leukemia, CMML. | suspended | Phase 1 | 30 | Huda SalmanOTHER | 1 | Sep 24, 2026 | clinicaltrials |
| NCT06136559 | A Study of Nemtabrutinib (MK-1026) Versus Comparator (Investigator's Choice of Ibrutinib or Acalabrutinib) in First Line (1L) Chronic Lymphocytic Leukemia (CLL)/ Small Lymphocytic Lymphoma (SLL) (MK-1026-011/BELLWAVE-011) | recruiting | Phase 3 | 1,200 | Merck Sharp & Dohme LLCINDUSTRY | 29 | Sep 24, 2026 | clinicaltrials |
| NCT06197672 | Chimeric Antigen Receptor T Cell Redirected to Target CD4 Positive Relapsed Refractory Acute Myeloid Leukemia (AML ) as a Bridge to Allogeneic Stem Cell Transplant | suspended | Phase 1 | 30 | Huda SalmanOTHER | 1 | Sep 24, 2026 | clinicaltrials |
| NCT06398457 | Darzalex Faspro (Daratumumab and Hyaluronidase-fihj) Before Standard Desensitization and Allogeneic Peripheral Blood Stem Cell Transplantation in Adult Patients at High-risk for Primary Graft Failure Secondary to Donor Specific Antibodies | recruiting | Early Phase 1 | 8 | Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsOTHER | 1 | Sep 24, 2026 | clinicaltrials |
| NCT06529575 | Evaluating the Relationship Between Skin Color and Pulse Oximeter Accuracy in Children(PACH) | recruiting | — | 650 | University of PennsylvaniaOTHER | 1 | Sep 24, 2026 | clinicaltrials |
Data updated 5 days agoSource updated Sep 25, 2026source: clinicaltrials